Bladder Ca test identifies those at low risk of recurrence
Pacific Edge Ltd. has launched its bladder cancer test, Cxbladder Monitor, in the United States. The noninvasive test is designed to be used as part of patients’ ongoing surveillance regimen to identify those who have a low probability of having recurrent cancers. Based on test results, patients may not need a cystoscopy or other invasive workup or can increase the intervals between invasive workups, according to Pacific Edge. Pacific Edge also offers the Cxbladder Triage, which helps to rule out cancer in patients who have a low probability of having bladder cancer, and Cxbladder Detect, which is used to specifically detect bladder cancer. A fourth test, for identifying patients with high-grade and late-stage bladder cancer, is expected to launch in the U.S. in 2017.
For more information, visit www.pacificedgedx.com.